Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
14.87
+0.91 (6.52%)
At close: Aug 10, 2026, 4:00 PM EDT
14.99
+0.12 (0.81%)
Pre-market: Aug 11, 2026, 7:29 AM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
11.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.21B |
| Corcept Therapeutics | 830.81M |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 669.50M |
| Cytokinetics | 67.67M |
SMMT News
- 4 days ago - These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks - Barrons
- 4 days ago - Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - GlobeNewsWire
- 6 days ago - Summit announces expansion of development program for ivonescimab - TheFly
- 6 days ago - Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business Wire
- 17 days ago - Summit Therapeutics price target lowered to $15 from $17 at Jefferies - TheFly
- 17 days ago - H.C. Wainwright keeps Neutral on Summit Therapeutics after Q2 report - TheFly
- 18 days ago - Summit Therapeutics price target lowered to $38 from $45 at Stifel - TheFly
- 18 days ago - Summit Therapeutics price target lowered to $38 from $40 at Guggenheim - TheFly